OmniAb Inc. (OABI)vsBeiGene, Ltd. (ONC)
OABI
OmniAb Inc.
$1.67
-5.11%
HEALTHCARE · Cap: $254.82M
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 28524% more annual revenue ($5.34B vs $18.67M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
OABI
Avoid27
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for OABI.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : OABI
The strongest argument for OABI centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Profit Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
OABI profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
OABI carries more volatility with a beta of 0.85 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 27/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies through its proprietary OmniAb platform. This advanced technology enables the efficient discovery and optimization of high-quality therapeutics aimed at addressing a wide array of diseases. With a strategic emphasis on collaborations and partnerships, OmniAb is committed to accelerating drug development processes and enhancing the availability of breakthrough treatments. Led by a skilled management team and supported by a robust pipeline, the company is poised to capitalize on the growing opportunities within the biopharmaceutical sector.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?